tiprankstipranks
Trending News
More News >
Third Harmonic Bio, Inc. (THRD)
:THRD
US Market
THRD
Third Harmonic Bio, Inc.
RESEARCH TOOLSreports

Third Harmonic Bio, Inc. (THRD) Price & Analysis

Compare
Followers

THRD Stock Chart & Stats

$5.38
$0.00(0.00%)
--

Third Harmonic Bio, Inc. News

THRD FAQ

What was Third Harmonic Bio, Inc.’s price range in the past 12 months?
Currently, no data Available
What is Third Harmonic Bio, Inc.’s market cap?
Currently, no data Available
When is Third Harmonic Bio, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Third Harmonic Bio, Inc.’s earnings last quarter?
Currently, no data Available
Is Third Harmonic Bio, Inc. overvalued?
According to Wall Street analysts Third Harmonic Bio, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
    Does Third Harmonic Bio, Inc. pay dividends?
    Third Harmonic Bio, Inc. does not currently pay dividends.
    What is Third Harmonic Bio, Inc.’s EPS estimate?
    Third Harmonic Bio, Inc.’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does Third Harmonic Bio, Inc. have?
    Currently, no data Available
    What happened to Third Harmonic Bio, Inc.’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of Third Harmonic Bio, Inc.?
    Currently, no hedge funds are holding shares in THRD
    What is the TipRanks Smart Score and how is it calculated?
    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

      Company Description

      Third Harmonic Bio, Inc.

      Third Harmonic Bio, Inc. (THRD) is a biopharmaceutical company focused on the discovery and development of innovative therapies for the treatment of allergic and inflammatory diseases. Leveraging its expertise in immunology and drug development, the company aims to address unmet medical needs by creating targeted therapies that modulate specific pathways involved in allergic and inflammatory responses.

      Ownership Overview

      0.08%99.77%
      Insiders
      0.08%
      Mutual Funds
      ― Other Institutional Investors
      99.77% Public Companies and
      Individual Investors

      Options Prices

      Currently, No data available
      ---
      Popular Stocks